CN102036673A - 特应性皮炎预防剂和/或治疗剂 - Google Patents
特应性皮炎预防剂和/或治疗剂 Download PDFInfo
- Publication number
- CN102036673A CN102036673A CN2009801189107A CN200980118910A CN102036673A CN 102036673 A CN102036673 A CN 102036673A CN 2009801189107 A CN2009801189107 A CN 2009801189107A CN 200980118910 A CN200980118910 A CN 200980118910A CN 102036673 A CN102036673 A CN 102036673A
- Authority
- CN
- China
- Prior art keywords
- extract
- peel
- atopic dermatitis
- therapeutic agent
- test
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 36
- 206010012438 Dermatitis atopic Diseases 0.000 title claims abstract description 34
- 201000008937 atopic dermatitis Diseases 0.000 title claims abstract description 34
- 229940124597 therapeutic agent Drugs 0.000 title claims abstract description 22
- 239000000284 extract Substances 0.000 claims abstract description 66
- 240000006053 Garcinia mangostana Species 0.000 claims abstract description 33
- 235000017048 Garcinia mangostana Nutrition 0.000 claims abstract description 33
- 235000013305 food Nutrition 0.000 claims abstract description 15
- 239000002798 polar solvent Substances 0.000 claims abstract description 11
- 230000003449 preventive effect Effects 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- 238000000605 extraction Methods 0.000 claims description 15
- 208000003251 Pruritus Diseases 0.000 claims description 3
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims 4
- 239000004615 ingredient Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 22
- 201000004624 Dermatitis Diseases 0.000 abstract description 9
- 238000011160 research Methods 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract description 2
- 241000283690 Bos taurus Species 0.000 abstract 2
- 238000012360 testing method Methods 0.000 description 44
- 238000002360 preparation method Methods 0.000 description 26
- VEZXFTKZUMARDU-UHFFFAOYSA-N gamma-mangostin Chemical compound OC1=C(O)C(CC=C(C)C)=C2C(=O)C3=C(O)C(CC=C(C)C)=C(O)C=C3OC2=C1 VEZXFTKZUMARDU-UHFFFAOYSA-N 0.000 description 16
- 239000000419 plant extract Substances 0.000 description 13
- 238000006748 scratching Methods 0.000 description 13
- 230000002393 scratching effect Effects 0.000 description 13
- 239000002674 ointment Substances 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- 238000000576 coating method Methods 0.000 description 11
- 239000011248 coating agent Substances 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- ACRGTLGOYYTGNX-UHFFFAOYSA-N gamma-mangostin Natural products OC1=C(O)C=C2C(=O)C3=C(O)C(CC=C(C)C)=C(O)C=C3OC2=C1 ACRGTLGOYYTGNX-UHFFFAOYSA-N 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 235000013599 spices Nutrition 0.000 description 8
- 150000003431 steroids Chemical class 0.000 description 8
- QTDMGAWIBXJNRR-UHFFFAOYSA-N Mangostin Natural products CC(=CCc1c(O)cc2Oc3cc(C)c(O)c(CC=C(C)C)c3C(=O)c2c1O)C QTDMGAWIBXJNRR-UHFFFAOYSA-N 0.000 description 7
- GNRIZKKCNOBBMO-UHFFFAOYSA-N alpha-mangostin Chemical compound OC1=C(CC=C(C)C)C(O)=C2C(=O)C3=C(CC=C(C)C)C(OC)=C(O)C=C3OC2=C1 GNRIZKKCNOBBMO-UHFFFAOYSA-N 0.000 description 7
- ZVFQDLCERPGZMO-UHFFFAOYSA-N alpha-mangostin Natural products OC1=C(CC=C(C)C)C(O)=C2C(=O)C3=C(CC=C(C)C)C(OC)=C(O)C=C3CC2=C1 ZVFQDLCERPGZMO-UHFFFAOYSA-N 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- GUBGYTABKSRVRQ-PICCSMPSSA-N D-Maltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 6
- 241000209051 Saccharum Species 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 235000013312 flour Nutrition 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000002085 persistent effect Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 240000008042 Zea mays Species 0.000 description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 3
- 230000001387 anti-histamine Effects 0.000 description 3
- 239000000739 antihistaminic agent Substances 0.000 description 3
- 235000005822 corn Nutrition 0.000 description 3
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010003645 Atopy Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 241000832224 Hypericaceae Species 0.000 description 2
- 102000001284 I-kappa-B kinase Human genes 0.000 description 2
- 108060006678 I-kappa-B kinase Proteins 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 206010048908 Seasonal allergy Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 239000000043 antiallergic agent Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 235000013360 fish flour Nutrition 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 235000015205 orange juice Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000009781 safety test method Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- 239000006200 vaporizer Substances 0.000 description 2
- 235000008939 whole milk Nutrition 0.000 description 2
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 description 1
- IOYNGCZNYGEZRO-UHFFFAOYSA-N 3-ethyl-n,n,2-trimethyl-1h-indol-5-amine Chemical compound C1=C(N(C)C)C=C2C(CC)=C(C)NC2=C1 IOYNGCZNYGEZRO-UHFFFAOYSA-N 0.000 description 1
- 241000962514 Alosa chrysochloris Species 0.000 description 1
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 206010016936 Folliculitis Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 235000007230 Sorghum bicolor Nutrition 0.000 description 1
- 235000019764 Soybean Meal Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- -1 Sucrose fatty acid ester Chemical class 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 206010048218 Xeroderma Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940036811 bone meal Drugs 0.000 description 1
- 239000002374 bone meal Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000003153 cholinolytic effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 235000020965 cold beverage Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000021185 dessert Nutrition 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 235000011869 dried fruits Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000021433 fructose syrup Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229940112971 protopic Drugs 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229960004711 sodium monofluorophosphate Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- CMXPERZAMAQXSF-UHFFFAOYSA-M sodium;1,4-bis(2-ethylhexoxy)-1,4-dioxobutane-2-sulfonate;1,8-dihydroxyanthracene-9,10-dione Chemical compound [Na+].O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O.CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC CMXPERZAMAQXSF-UHFFFAOYSA-M 0.000 description 1
- 239000004455 soybean meal Substances 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/111—Aromatic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/116—Heterocyclic compounds
- A23K20/121—Heterocyclic compounds containing oxygen or sulfur as hetero atom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Birds (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Medicines Containing Plant Substances (AREA)
- Fodder In General (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明人为了提供产生副作用等的可能性低、安全性高的特应性皮炎的预防剂和/或治疗剂进行了认真研究,结果发现,用极性溶剂从山竹(Garcinia mangostana L.)的果皮萃取的提取物可预防或治疗特应性皮炎。即,本发明提供由用极性溶剂从山竹的果皮萃取的提取物组成的特应性皮炎预防剂和/或治疗剂。此外,本发明提供含有所述特应性皮炎预防剂和/或治疗剂的食品。
Description
技术领域
本发明涉及由山竹的果皮提取物组成的特应性皮炎预防剂和/或治疗剂。
背景技术
特应性皮炎是反复恶化、缓解且以发痒的湿疹为主要病变的疾病,患者多具有特应性素质。特应性素质是指:(1)家族史、既往史,(2)容易产生IgE抗体的素质。
特应性皮炎的主要病变有皮肤的红斑或丘疹、耳下裂纹、干皮症、伴有糠秕状鳞屑的毛孔一致性角化性丘疹,患者皮肤的抓挠会产生印痕。根据近年的调查,特应性皮炎的患病率为:4个月大的儿童12.8%,1岁半的儿童9.8%,3岁的儿童13.2%,小学一年级学生11.8%,小学六年级学生10.6%,大学一年级学生8.2%,在儿童中患病率高达每10人中有1人患病。病因、恶化因素主要有食物、出汗、环境因子、细菌真菌、接触抗原、精神压力等。
特应性皮炎的治疗通过以下方法进行:1)病因、恶化因素的检索和应对,2)皮肤护理,3)药物疗法。用方法1)、2)无法减轻症状时进行药物治疗。药物中使用最广泛的是类固醇外用药,有多种类固醇外用药。这些类固醇外用药根据临床效果分为从弱到最强的5级,根据患者的患病严重程度和年龄分别使用。另一方面,作为非类固醇类外用药,免疫调节剂普特彼(protopic)的有用性在近年得到了确认。此外,作为口服药,使用抗组胺药、抗过敏药等,但对于患病程度最严重的患者,有时会暂时使用类固醇的内服药。
但是,类固醇在用作外用药时,可能会伴有皮肤的萎缩、血管扩张、毛囊炎等副作用,根据由厚生劳动科学研究班制作的指导手册的指导,在面部应尽可能避免使用类固醇外用药。此外,对于类固醇药物,有很多患者担心其副作用而表现出排斥反应。另一方面,普特彼是于1999年11月认可使用的较新的药剂,对于未满16岁的患者只认可低浓度下的使用,对于2岁以下的幼儿,低浓度下的使用也不被认可。作为内服药的抗组胺药、抗过敏药可能会引起困倦、乏力或伴随抗胆碱作用的痰的咳出困难等副作用。
因此,要求开发出副作用小且可简便地使用的药物,进行了在来源于天然物的提取物中寻找能作为特应性皮炎的预防剂或治疗剂的物质的研究。
此外,已知特应性皮炎在狗、猫、家畜等人以外的动物中也会发病,要求进行其预防、治疗。
金丝桃科植物山竹(Garcinia mangostana L.)的果皮在泰国作为偏方用于止泻或炎症治疗,近年有报道称山竹果皮中所含的α-倒捻子素、γ-倒捻子素可抑制过敏反应。
日本专利特许第3968405中揭示:从山竹提取物中纯化的α-倒捻子素和γ-倒捻子素具有抗组胺效果或抗5-羟色胺效果,且α-倒捻子素和γ-倒捻子素显示出对人花粉症的抑制效果。日本专利特开2005-298379中揭示:山竹提取物、即α-倒捻子素、γ-倒捻子素具有对IκB激酶的抑制效果。日本专利特开2001-278770中揭示:金丝桃科植物的提取物具有缓解精神压力的影响的效果。
此外,也进行了用于阐明山竹提取物的抗过敏效果的机理的研究。Biol.Pharm.Bull.,25,p1137(2002)中揭示:山竹提取物可抑制组胺的释放以及前列腺素E的合成。Eur.J.Pharmacol.,314,p351(1996)中揭示:α-倒捻子素是组胺H受体的拮抗剂。Mol.Pharmacol.,66,p667(2004)中揭示:γ-倒捻子素可抑制IκB激酶活性,抑制前列腺素E的释放,其结果是抑制环加氧酶2基因的表达。Biochem.Pharmacol.,63,p73(2002)中揭示:γ-倒捻子素可抑制环加氧酶和前列腺素E2的合成。
对山竹果皮的提取物进行了各种安全性试验。日本专利特开平5-17365的0015段中用小鼠进行了采用口服给药的急性毒性试验,结果显示,即使给予10g/Kg的山竹果皮提取物,也未观察到死亡例。另外,在日本专利特开平4-244004的0047段所示的安全性试验中,进行了将山竹果皮提取物涂布于人皮肤的刺激性试验,结果显示,刺激性极低,其安全性高。
发明的揭示
日本专利特许第3968405和日本专利特开2005-298379中揭示:从山竹提取物中纯化的α-倒捻子素、γ-倒捻子素具有抗过敏效果,且α-倒捻子素和γ-倒捻子素显示出对人花粉症的抑制效果。但是,这些文献中未研究对特应性皮炎的效果。本发明的目的是提供从山竹的果皮提取的特应性皮炎的预防剂和/或治疗剂。
本发明人为了获得产生副作用等的可能性低、安全性高的特应性皮炎的预防剂和/或治疗剂进行了认真研究,结果发现,用极性溶剂从山竹的果皮萃取的物质可预防或治疗特应性皮炎,从而完成了本发明。
即,本发明提供由用极性溶剂从山竹的果皮萃取的提取物组成的特应性皮炎预防剂和/或治疗剂。此外,本发明提供含有所述特应性皮炎预防剂和/或治疗剂的食品。
本发明的由用极性溶剂从山竹的果皮萃取的提取物组成的特应性皮炎预防剂和/或治疗剂也可用于宠物、家畜和/或家禽、特别是狗和/或猫。此外,本发明提供含有由用极性溶剂从山竹的果皮萃取的提取物组成的特应性皮炎预防剂和/或治疗剂的饲料。
山竹的果皮可使用从山竹果实(新鲜或干燥物)得到的果皮。山竹的果皮可直接使用,但如果考虑到提高萃取率,则较好是在粉碎或制成粉末后进行萃取。此外,也可在萃取前用非极性溶剂将山竹果皮脱脂。
采用选自作为极性溶剂的甲醇、乙醇、正丙醇、2-丙醇、正丁醇、丙酮、乙酸乙酯和水的至少1种极性溶剂来实施萃取。也可将2种以上的溶剂组合起来实施萃取。另外,如果考虑到用作口服剂或饮食品、饲料等的情况,则作为萃取溶剂,从安全性的角度来看优选使用乙醇或水与乙醇的组合。萃取的温度无特别限定,从萃取效率的角度来看,较好是在室温到溶剂的沸点温度的范围内。萃取时间根据溶剂的种类、果皮的状态(新鲜或干燥物、粉碎物或粉末等)和萃取温度而变化,较好是在0.5~24小时的范围内。
提取物可根据需要用蒸发器等将萃取溶剂浓缩或除去。此外,提取物也可根据需要通过溶剂分提或色谱法进行纯化后使用。
本发明的特应性皮炎预防剂和/或治疗剂可添加于清凉饮料、点心、冷饮、乳制品、酒类和肉类等食品以及饲料。
作为特应性皮炎预防剂和/或治疗剂的山竹果皮提取物的给药量根据给药方法和所需的治疗而变化,不能一概而论,提取物的量为每1kg动物60~250mg,对人而言是0.3mg~300mg/kg体重/天、更好是0.5mg~200mg/kg体重/天。
本发明的特应性皮炎预防剂和/或治疗食品可按照作为食品的1天的常规摄取量满足上述有效量的条件来规定掺入量。1天的量也可分数次摄取。
此外,本发明的特应性皮炎预防剂和/或治疗用饲料可按照作为饲料的1天的常规摄取量满足上述有效量的条件来规定掺入量。1天的量也可分数次摄取。
根据本发明,可利用山竹的果皮提取物来预防或治疗特应性皮炎。此外,本发明的提取物是用极性溶剂从山竹中萃取的,即使不进行进一步的纯化也可获得上述效果。如果给予本发明的山竹果皮提取物,则可观察到与涂布普特彼软膏的组同等或在其之上的效果。通过给予本发明的山竹果皮提取物,血中总IgE值的上升得到抑制,提示过敏反应得到了全身性的抑制。
此外,山竹被称为果后,其果实可供食用,知名度也高,是印象良好的素材。因此,由山竹果皮的提取物组成的特应性皮炎预防剂和/或治疗剂不会带来由风评引起的不安,容易让患者接受。此外,含有由山竹果皮的提取物组成的特应性皮炎预防剂和/或治疗剂的饲料在用于将来会被用作食品的家畜时也容易让人接受,此外,在用于狗、猫等宠物时也容易让宠物爱好者接受。
附图的简单说明
图1是表示各组的临床症状评分随时间的变化的图。
图2是表示各组的试验开始前后的抓挠行为次数的图。
图3是表示各组的试验开始前后的抓挠行为时间的图。
图4是表示各组的试验开始前后的血中IgE值的图。
图5是表示各组的经表皮水分丢失量随时间的变化的图。
图6是表示各组的体重随时间的变化的图。
实施发明的最佳方式
下面例举本发明的例子进行说明,但本发明的范围不限定于以下的例子。
实施例1
如下所述获得山竹果皮提取物。即,将山竹的100g未干燥果皮粉碎,在11的70%乙醇中于80℃搅拌萃取1小时。对其进行过滤,用蒸发器对滤液进行减压干燥,得到27.4g提取物。
实施例2
对山竹果皮提取物的摄取对由过敏引起的皮炎的症状改善所起到的效果进行了特应性皮炎自然发病模型小鼠验证。
试验中,使用5-6周龄的特应性皮炎自然发病模型小鼠NC/NgaTnd小鼠。这些实验动物在实验开始前进行1周的预饲养后,分成山竹果皮提取物喂食组、对照饲料喂食组、普特彼软膏涂布组这3组(N=7)来进行实验。统计学处理用Dunnett的多重比较检验或斯氏检验(t检验)。
将实施例1中得到的山竹果皮提取物按照0.25%W/W的比例混入饲料(CRF-1,东方酵母公司(オリエンタル酵母社)制),制成山竹果皮提取物粉末混合饲料。按照山竹提取物的摄取量为250mg/kg/天的量让山竹果皮提取物喂食组的NC/NgaTnd小鼠自然摄取该饲料。让对照饲料喂食组的NC/NgaTnd小鼠自然摄取普通饲料(CRF-1)。让普特彼软膏涂布组的NC/NgaTnd小鼠与对照饲料喂食组同样地自然摄取普通饲料(CRF-1),以1天1次、1周5次的频率进行普特彼(0.1%软膏)的涂布。各组中,饲料和水均自由摄取。
对上述3组进行皮炎评分的判定。判定方法以Matsuda,H.等.,Int.Immunol.9:461-466,1997为参考如下所述进行。即,从开始喂食试验食物的前一天及开始喂食当天起到最后一次喂食的后一天为止,每周2次对“挠痒症状”、“红斑/出血”、“浮肿”、“擦伤/糜烂”、“落屑/干燥”这5个项目进行判定,判定分为“0:无”、“1:轻度”、“2:中度”、“3:重度”4级。另外,判定人员和喂食人员在试验期间由不同人员进行,判定人员不知道动物属于哪一组。结果示于表1、图1。图1中,○表示山竹果皮提取物喂食组,△表示对照饲料喂食组,□表示普特彼软膏涂布组。
表1各组的临床症状评分的平均值和标准差
(A:山竹果皮提取物喂食组N=8,B:对照饲料喂食组N=7,C:普特彼软膏涂布组N=7)
所有组中,试验开始时的临床症状评分为0(未发病)。对照饲料喂食组中,自试验开始3天后起可观察到临床症状评分随时间上升,试验结束时的临床症状评分为5.0±1.0。普特彼软膏涂布组中,自试验开始14天后起可观察到轻度的皮炎发病,试验结束时的临床症状评分为2.6±0.8。山竹果皮提取物喂食组中,自试验开始3天后起可观察到极轻度的皮炎症状,但未表现出明显的恶化,试验结束时的临床症状评分仍保持较低,为1.3±0.4。普特彼软膏涂布组中,从试验开始第3天到第28天为止维持了显著低于对照饲料喂食组的临床症状评分,但试验开始第31天后未观察到统计学上的显著差异。另一方面,山竹果皮提取物喂食组中,从试验开始第14天后到试验结束为止,在临床症状评分的抑制方面未观察到统计学上的显著差异。此外,在整个试验期间,未见因山竹果皮提取物喂食而导致的明显副作用。
实施例3
对与上述同样的3组进行了挠痒次数和持续时间的测定,对山竹果皮提取物的摄取对由过敏引起的皮炎的症状改善所起到的效果进行了验证。测定以Orito,K.等.Brit.J.Dermatol.150:1-6,2004为参考如下所述进行。为了使所有组的小鼠适应测定环境,自开始喂食试验食物前3天起,使所有组的小鼠在抓挠次数测定装置(SCLABA,诺华泰克公司(ノベルテツク社)制)内进行适应,频率为1天1次,共进行2天,每次20分钟。试验开始前的抓挠次数和持续时间的测定中,在开始喂食的前一天使小鼠适应20分钟后,进行20分钟的拍摄和记录。与上述同样地在结束喂食试验食物前使小鼠适应后,在试验结束日的后一天进行抓挠次数及持续时间的拍摄和记录。另外,拍摄中记录拍摄日期和个体编号,在12点~18点间进行拍摄。
结果示于图2、图3。所有组中,试验开始时的抓挠频率(Scratching Frequency)和抓挠时间(Scratching Duration)(秒)在每20分钟的拍摄时间内分别为1次和0.2秒左右。在任何一组中,与试验开始前(喂食试验食物的前一天)相比,试验结束后(结束喂食试验食物的后一天)均显示出抓挠行为增加的倾向,但山竹果皮提取物喂食组和普特彼软膏涂布组无统计学上的显著差异。另一方面,对照饲料喂食组中,与试验开始前相比,在试验结束时观察到抓挠行为的显著增加。
实施例4
对与上述同样的3组进行了血中IgE浓度的测定,对山竹果皮提取物的摄取对由过敏引起的皮炎的症状改善所起到的效果进行了验证。IgE浓度测定以Tanaka,A.等,J.Invest.Dermatol.127:855-863,2007为参考如下所述进行。开始喂食前通过尾静脉采集约1ml血液,在结束喂食当天进行抓挠次数和持续时间的拍摄/记录后,进行乙醚麻醉,然后用经肝素处理的注射器通过腹大动脉采集约1ml血液。所采集的血液通过4℃下的离心分离得到血浆,于-20℃冻存。IgE的测定采用识别2种不同的表位的抗小鼠IgE抗体(ME-01-DE及ME-02-B,均为雅玛山公司(ヤマサ社)制)通过三明治ELISA法进行。
结果示于图4。试验开始前的血中总IgE(ng/ml)在山竹果皮提取物喂食组中为531±104,在对照饲料喂食组中为782±108,在普特彼软膏涂布组中为556±207,在组间未观察到统计学上的显著差异。在任一组中,与试验开始前相比,试验结束后均显示出血中总IgE值增加的倾向,与对照饲料喂食组相比,在山竹果皮提取物喂食组和普特彼软膏涂布组中均观察到血中总IgE值上升的统计学上的显著抑制。
实施例5
对与上述同样的3组进行了经表皮水分丢失量(TEWL)的测定,对山竹果皮提取物的摄取对由过敏引起的皮炎的症状改善所起到的效果进行了验证。TEWL的测定中,在测定前一天将小鼠背部剃毛,用多探头皮肤测试系统(Multi Probe Adapter)(CK电子公司(CK electronic社)制)测定背部的TEWL。对每1个体测定3次,将其平均值作为TEWL值。在试验前和试验结束后进行总共2次测定,并且在此期间的2周内进行1次测定。
结果示于图5。所有组中,试验开始时的TEWL为5g/hr/m2,处于正常范围内。试验开始第2周后,TEWL显示出上升的倾向,特别是对照饲料喂食组中,TEWL随时间上升,在试验结束时显示出29.7±7.6g/hr/m2的高值。普特彼软膏涂布组中,TEWL到试验开始第4周为止都同样地上升,但在试验结束时为17.1±7.6g/hr/m2,显示出低于对照饲料喂食组的倾向,但未观察到统计学上的显著差异。另一方面,山竹果皮提取物喂食组中,TEWL在整个试验期间均维持在低于10g/hr/m2的正常范围内,在试验结束时与对照饲料喂食组相比显示出统计学上显著较低的值。
实施例6
对与上述同样的3组进行了体重测定。用电子天平(HL-320,阿斯顿汉森公司(ア一ストハンセン社)制)自开始喂食试验食物的前一天起每隔2周进行体重测定。
结果示于图6。试验开始时的体重为20.0~23.6g。然后,各组的体重均随时间增加,对于体重增加率未观察到组间差异,未观察到由山竹给药引起的副作用。
实施例7
用实施例1中制备的植物提取物如下所述制备含片剂。
葡萄糖 72.3%
乳糖 18.0
阿拉伯树胶 6.0
香料 1.0
单氟磷酸钠 0.7
山竹果皮提取物 2.0
100.0%
实施例8
用实施例1中制备的植物提取物如下所述制备口香糖。
胶基 20.0%
砂糖 54.7
葡萄糖 14.5
糖稀 9.3
香料 0.5
山竹果皮提取物 1.0
100.0%
实施例9
用实施例1中制备的植物提取物如下所述制备糖果。
砂糖 50.0%
糖稀 33.4
柠檬酸 1.0
香料 0.2
山竹果皮提取物 1.0
水 14.4
100.0%
实施例10
用实施例1中制备的植物提取物如下所述制备软糖。
明胶 60.0%
糖稀 23.0
砂糖 7.5
植物油 4.5
甘露糖醇 2.9
柠檬汁 1.0
山竹果皮提取物 1.0
100.0%
实施例11
用实施例1中制备的植物提取物如下所述制备巧克力。
糖粉 40.8%
可可苦料 20.0
全脂奶粉 20.0
可可脂 17.0
甘露糖醇 1.0
山竹果皮提取物 1.0
香料 0.2
100.0%
实施例12
用实施例1中制备的植物提取物如下所述制备雪糕。
橙汁 25.0%
砂糖 25.0
蛋白 10.0
山竹果皮提取物 0.1
香料 0.1
水 39.8
100.0%
实施例13
用实施例1中制备的植物提取物如下所述制备冰淇淋。
脱脂奶粉 50.0%
鲜奶油 25.0
砂糖 10.0
蛋黄 10.0
山竹果皮提取物 1.0
香料 0.1
水 3.9
100.0%
实施例14
用实施例1中制备的植物提取物如下所述制备饼干。
低筋面粉1级 25.0%
中筋面粉1级 22.0
精制白糖 5.0
食盐 1.0
葡萄糖 1.0
棕榈起酥油 12.0
碳酸氢钠 0.2
亚硫酸氢钠 0.2
米粉 2.0
全脂奶粉 1.0
代奶粉 0.6
山竹果皮提取物 1.0
水 29.0
100.0%
实施例15
用实施例1中制备的植物提取物如下所述制备糖片。
砂糖 75.8%
葡萄糖 19.0
蔗糖脂肪酸酯 0.2
香料 0.2
山竹果皮提取物 0.8
水 4.0
100.0%
实施例16
用实施例1中制备的植物提取物如下所述制备饮料。
橙汁 30.0
高果糖浆 15.14
柠檬酸 0.1
维生素C 0.04
香料 0.1
山竹果皮提取物 0.2
水 54.42
100.0%
实施例17
用实施例1中制备的植物提取物如下所述制备狗饲料。
肉类食物原料(鸡肉、牛肉) 40.3
猪背脂肪 2.5
冰 19.0
植物蛋白 30.3
骨粉 3.8
食盐 0.4
聚合磷酸盐 0.2
糖类、调味料 2.5
山竹果皮提取物 1.0
100.0%
实施例18
用实施例1中制备的植物提取物如下所述制备猫饲料。
玉米 30.0
小麦粉 35.0
鱼粉 15.0
肉粉 8.9
牛油 4.0
食盐 1.0
鲣鱼提取物 5.0
维生素类 0.4
矿物质类 0.4
山竹果皮提取物 0.3
100.0%
实施例19
用实施例1中制备的植物提取物如下所述制备猪饲料。
玉米 65.0
高粱 5.0
脱脂糠 3.0
玉米胚芽粕 2.0
大豆粕 17.0
鱼粉 4.0
动物性油脂 2.0
碳酸钙 1.0
预混合料 0.9
山竹果皮提取物 0.1
100.0%
本申请主张基于2008年5月22日提出申请的日本专利申请号2008-134246的优先权,引用其内容作为本申请的一部分。
Claims (7)
1.一种特应性皮炎预防剂和/或治疗剂,其特征在于,由用极性溶剂从山竹(Garcinia mangostana L.)的果皮萃取的提取物组成。
2.如权利要求1所述的特应性皮炎预防剂和/或治疗剂,其特征在于,极性溶剂是乙醇或乙醇水溶液。
3.一种特应性皮炎预防剂和/或治疗剂,其特征在于,含有用乙醇或乙醇水溶液从山竹(Garcinia mangostana L.)的果皮萃取的提取物作为有效成分,可抑制IgE抗体的产生。
4.一种食品,其特征在于,含有权利要求1~3中的任一项所述的特应性皮炎预防剂和/或治疗剂。
5.一种瘙痒预防和/或治疗用食品,其特征在于,含有山竹(Garcinia mangostana L.)果皮的乙醇或乙醇水溶液提取物作为有效成分。
6.一种饲料,其特征在于,含有权利要求1~3中的任一项所述的特应性皮炎预防剂和/或治疗剂。
7.一种瘙痒预防和/或治疗用饲料,其特征在于,含有山竹(Garcinia mangostana L.)果皮的乙醇或乙醇水溶液提取物作为有效成分。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008-134246 | 2008-05-22 | ||
JP2008134246 | 2008-05-22 | ||
PCT/JP2009/059492 WO2009142320A1 (ja) | 2008-05-22 | 2009-05-19 | アトピー性皮膚炎予防剤及び/または治療剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN102036673A true CN102036673A (zh) | 2011-04-27 |
Family
ID=41340244
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009801189107A Pending CN102036673A (zh) | 2008-05-22 | 2009-05-19 | 特应性皮炎预防剂和/或治疗剂 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20110076348A1 (zh) |
EP (1) | EP2301558A4 (zh) |
JP (1) | JPWO2009142320A1 (zh) |
KR (1) | KR20110010797A (zh) |
CN (1) | CN102036673A (zh) |
TW (1) | TW201000113A (zh) |
WO (1) | WO2009142320A1 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106361784A (zh) * | 2015-07-24 | 2017-02-01 | 山酮新药开发股份有限公司 | 山竹果果壳萃取物用于治疗皮肤疾病的用途 |
TWI627960B (zh) * | 2015-07-24 | 2018-07-01 | 山酮新藥開發股份有限公司 | 山竹果果殼萃取物用於治療皮膚疾病之用途 |
WO2022213665A1 (en) * | 2021-04-09 | 2022-10-13 | Xantho Biotechnology Co., Ltd | Use of mangosteen fruit shell extract in the preparation of a medicament for treating bedsores |
WO2023155158A1 (en) * | 2022-02-18 | 2023-08-24 | Xantho Biotechnology Co., Ltd | Use of mangosteen fruit shell extract in the preparation of a medicament for promoting wound healing in diabetes |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20120027172A (ko) * | 2009-03-31 | 2012-03-21 | 가부시키가이샤 롯데 | 피부 장해의 치료 및/또는 예방을 위한 조성물 |
KR20150036556A (ko) * | 2012-07-19 | 2015-04-07 | 가부시키가이샤 롯데 | 면역 조절제 |
EP3175887B1 (fr) * | 2015-12-01 | 2020-06-24 | Denis Bernhard | Creme cosmetique de sudation |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2890212B2 (ja) | 1991-01-29 | 1999-05-10 | 有限会社野々川商事 | 化粧料 |
JP3010566B2 (ja) | 1991-07-03 | 2000-02-21 | 有限会社野々川商事 | テストステロン 5α−レダクターゼ阻害剤 |
JPH07250658A (ja) * | 1994-03-11 | 1995-10-03 | Dainippon Ink & Chem Inc | 抗菌剤 |
JP3968405B2 (ja) * | 1996-08-30 | 2007-08-29 | 株式会社ロッテホールディングス | 抗アレルギー剤 |
JP2001278770A (ja) | 2000-03-30 | 2001-10-10 | Pola Chem Ind Inc | ストレスの影響緩和剤及びそれを含有してなる皮膚外用剤 |
JP5140231B2 (ja) | 2004-04-08 | 2013-02-06 | 株式会社ロッテ | IκBキナーゼ阻害剤 |
EP1824442A4 (en) * | 2004-11-16 | 2009-11-11 | Renaissance Herbs Inc | PHARMACEUTICAL AND THERAPEUTIC COMPOSITIONS DERIVED FROM GARCINIA MANGOSTANA L. |
JP2006169149A (ja) * | 2004-12-15 | 2006-06-29 | Hosoda Shc:Kk | 皮膚表皮基底細胞増殖促進剤 |
US7581427B2 (en) | 2006-11-14 | 2009-09-01 | Mocon, Inc. | Workspace analyte sensing system and method using a fan to move samples from the workspace to the sensor |
-
2009
- 2009-05-19 JP JP2010513077A patent/JPWO2009142320A1/ja active Pending
- 2009-05-19 WO PCT/JP2009/059492 patent/WO2009142320A1/ja active Application Filing
- 2009-05-19 EP EP09750682A patent/EP2301558A4/en not_active Withdrawn
- 2009-05-19 US US12/993,836 patent/US20110076348A1/en not_active Abandoned
- 2009-05-19 KR KR1020107028570A patent/KR20110010797A/ko not_active Application Discontinuation
- 2009-05-19 CN CN2009801189107A patent/CN102036673A/zh active Pending
- 2009-05-22 TW TW098117186A patent/TW201000113A/zh unknown
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106361784A (zh) * | 2015-07-24 | 2017-02-01 | 山酮新药开发股份有限公司 | 山竹果果壳萃取物用于治疗皮肤疾病的用途 |
WO2017016428A1 (zh) * | 2015-07-24 | 2017-02-02 | 山酮新药开发股份有限公司 | 山竹果果壳萃取物用于制备治疗皮肤疾病的药物的用途 |
TWI627960B (zh) * | 2015-07-24 | 2018-07-01 | 山酮新藥開發股份有限公司 | 山竹果果殼萃取物用於治療皮膚疾病之用途 |
CN106361784B (zh) * | 2015-07-24 | 2020-08-14 | 山酮新药开发股份有限公司 | 山竹果果壳萃取物用于治疗皮肤疾病的用途 |
WO2022213665A1 (en) * | 2021-04-09 | 2022-10-13 | Xantho Biotechnology Co., Ltd | Use of mangosteen fruit shell extract in the preparation of a medicament for treating bedsores |
WO2023155158A1 (en) * | 2022-02-18 | 2023-08-24 | Xantho Biotechnology Co., Ltd | Use of mangosteen fruit shell extract in the preparation of a medicament for promoting wound healing in diabetes |
Also Published As
Publication number | Publication date |
---|---|
WO2009142320A1 (ja) | 2009-11-26 |
EP2301558A1 (en) | 2011-03-30 |
TW201000113A (en) | 2010-01-01 |
EP2301558A4 (en) | 2012-01-18 |
JPWO2009142320A1 (ja) | 2011-09-29 |
KR20110010797A (ko) | 2011-02-07 |
US20110076348A1 (en) | 2011-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102036673A (zh) | 特应性皮炎预防剂和/或治疗剂 | |
US8518462B2 (en) | Compound comprising extracts or fractions of chrysanthemum boreale makino having anti-inflammation activity | |
US9066536B2 (en) | Compositions and methods for increasing the suppression of hunger and reducing the digestibility of non-fat energy satiety | |
KR101495117B1 (ko) | 꾸지뽕나무 줄기 추출물을 함유하는 아토피 질환 치료용 조성물 | |
US20140275233A1 (en) | Activated soy pod fiber | |
MX2007010408A (es) | Composiciones que comprenden actinidia y sus metodos de uso. | |
JPWO2002045733A1 (ja) | 鎮痒または抗掻痒活性を有する経口剤 | |
US20140228297A1 (en) | Preventive agent for atopic dermatitis | |
US20170065554A1 (en) | Activated soy pod fiber | |
KR101217181B1 (ko) | 탄닌산 및 퀘르세틴을 유효성분으로 함유하는 아토피성 피부염 예방, 개선 또는 치료용 조성물 | |
KR101700348B1 (ko) | 까마귀쪽나무 잎 또는 그 열매 추출물을 이용한 관절염 개선용 조성물 | |
US20080175888A1 (en) | Combination Therapy Comprising Actinidia and Steroids and Uses Thereof | |
Chatuevedi et al. | Diversified therapeutic potential of Avena sativa: An exhaustive review | |
US20070036872A1 (en) | Alpha-glucosidase activity inhibitor | |
KR102037944B1 (ko) | 무메푸랄을 포함하는 인지장애 관련 질환의 예방 또는 치료용 조성물 | |
KR102287877B1 (ko) | 차전자피를 포함하는 기억력 및 인지기능 증진용 조성물 | |
Islam et al. | Antidiarrheal, analgesic, and anthelmintic activities of honeys in the Sundarbans mangrove forest, Bangladesh | |
Adeoye et al. | Feeding behaviour, weight gain and blood sugar of male wistar rats fed on a high-calorie diet and vegetables | |
TWI832945B (zh) | 血糖值上昇抑制用、血中三酸甘油酯上昇抑制用組成物 | |
JP7143073B2 (ja) | 肌質改善組成物 | |
US20210267912A1 (en) | Methyl sulfonyl methane-containing composition for preventing or alleviating obesity, fatty liver, and diabetes | |
JP2023116773A (ja) | 皮膚水分量、皮膚油分量の増加及び/又は維持剤 | |
KR20220105696A (ko) | 복합성분을 유효성분으로 포함하는 면역력 증진 또는 피로 개선용 조성물 | |
KR20200010790A (ko) | 더덕 추출물을 유효성분으로 함유하는 항천식용 조성물 | |
WO2005063228A1 (ja) | 耐糖能改善剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1155958 Country of ref document: HK |
|
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20110427 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1155958 Country of ref document: HK |